Rfviii
Hematologic Disease
CSL BehringPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hematologic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Kogenate Bayer | Phase 4 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BB |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Same molecule, other indications
Rfviii is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →